Abstract
Simple SummaryPsoriasis and lichen planus are common skin diseases which have similar clinical presentation and pathogenesis. Considering these dermatoses are frequent and decrease patients’ life quality, it is important to look for different markers indicating patients’ condition which can possibly affect the choice of the treatment. MAdCAM-1 and ITGB7 molecules and their serum levels in patients with psoriasis and lichen planus have never been studied before; therefore, we are the first trying to analyze it in order to develop the current state of knowledge on psoriasis and lichen planus to better help patients.Plaque psoriasis (PSO) and lichen planus (LP) are skin diseases with some similarities in pathogenesis, comorbidities, and clinical presentation. Mucosal addressin cell adhesion molecule-1 (MAdCAM-1) and its ligand, α4β7 integrin, are involved in inflammatory bowel diseases and liver dysfunctions, which occur more frequently in PSO and LP. Serum MAdCAM-1 and ITGB7 levels in patients with plaque PSO and eruptive LP have never been studied before. The study included 42 patients with PSO, 13 with LP, and 23 controls. Serum molecules levels were evaluated using the immune–enzymatic method. ITGB7 concentration was not statistically different, both in patients with PSO and LP, compared to controls (both p > 0.05). MAdCAM-1 level was significantly lower in PSO subjects than in controls (p = 0.041), whereas in the LP group, a downward trend was observed (p = 0.088) with p = 0.0455 in ANOVA. Multiple linear regression revealed independent associations between ITGB7 and HDL and BMI and RBC in the LP group. In psoriatic patients with elevated CRP, there was an upward trend for MAdCAM-1, and also a positive correlation between MAdCAM-1 and WBC. ITGB7 and MAdCAM-1 cannot serve as markers of disease activity or liver pathology neither in patients with PSO nor LP. MAdCAM-1 might play a role as an inflammation indicator in PSO and a beneficial influence on the lipid profile in LP.
Highlights
There was correlation between MAdCAM-1 and white blood count (WBC) noted. This molecule cannot serve as a marker of disease activity or metabolic complications in patients with PSO, but it might play a role as an inflammation indicator in PSO patients; it requires further investigations
MAdCAM-1 and ITGB7 have been described to be involved in the NAFLD and nonalcoholic steatohepatitis (NASH) development, which are closely related to psoriasis, we found no correlation between these two molecules and markers of liver function
ITGB7 cannot serve as a marker of disease activity, inflammatory processes, or liver pathology neither in patients with PSO nor lichen planus (LP)
Summary
Psoriasis (PSO) is a common skin disease which affects 3% of population on average [1]. Its etiology is still a subject of investigation, but genetic, autoimmune, autoinflammatory, and environmental factors are taken into account [2]. Flares of PSO may be induced by infection, stress, alcohol, or a particular drug’s intake [3–5]. Key disorders that can be observed in psoriatic skin are keratinocytes hyperproliferation, abnormal differentiation and apoptosis, along with neoangiogenesis [2]. There are many types of psoriasis described, with the most common being plaque PSO [1].
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
